Correlation Between Pasithea Therapeutics and Cell Source
Can any of the company-specific risk be diversified away by investing in both Pasithea Therapeutics and Cell Source at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pasithea Therapeutics and Cell Source into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Pasithea Therapeutics Corp and Cell Source, you can compare the effects of market volatilities on Pasithea Therapeutics and Cell Source and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pasithea Therapeutics with a short position of Cell Source. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pasithea Therapeutics and Cell Source.
Diversification Opportunities for Pasithea Therapeutics and Cell Source
0.66 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Pasithea and Cell is 0.66. Overlapping area represents the amount of risk that can be diversified away by holding Pasithea Therapeutics Corp and Cell Source in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cell Source and Pasithea Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pasithea Therapeutics Corp are associated (or correlated) with Cell Source. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cell Source has no effect on the direction of Pasithea Therapeutics i.e., Pasithea Therapeutics and Cell Source go up and down completely randomly.
Pair Corralation between Pasithea Therapeutics and Cell Source
Given the investment horizon of 90 days Pasithea Therapeutics Corp is expected to under-perform the Cell Source. But the stock apears to be less risky and, when comparing its historical volatility, Pasithea Therapeutics Corp is 10.85 times less risky than Cell Source. The stock trades about -0.03 of its potential returns per unit of risk. The Cell Source is currently generating about 0.08 of returns per unit of risk over similar time horizon. If you would invest 40.00 in Cell Source on November 4, 2024 and sell it today you would lose (11.00) from holding Cell Source or give up 27.5% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 99.19% |
| Values | Daily Returns |
Pasithea Therapeutics Corp vs. Cell Source
Performance |
| Timeline |
| Pasithea Therapeutics |
| Cell Source |
Pasithea Therapeutics and Cell Source Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Pasithea Therapeutics and Cell Source
The main advantage of trading using opposite Pasithea Therapeutics and Cell Source positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pasithea Therapeutics position performs unexpectedly, Cell Source can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cell Source will offset losses from the drop in Cell Source's long position.| Pasithea Therapeutics vs. Nutriband Warrant | Pasithea Therapeutics vs. MediciNova | Pasithea Therapeutics vs. Virax Biolabs Group | Pasithea Therapeutics vs. Revelation Biosciences |
| Cell Source vs. Pasithea Therapeutics Corp | Cell Source vs. Nutriband Warrant | Cell Source vs. MediciNova | Cell Source vs. Virpax Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Complementary Tools
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |